| Trial ID: | L4495 |
| Source ID: | NCT01158417
|
| Associated Drug: |
Placebo
|
| Title: |
Resveratrol in Type2 Diabetes and Obesity
|
| Acronym: |
|
| Status: |
TERMINATED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Type 2 Diabetes|Obesity|Insulin Resistance
|
| Interventions: |
DRUG: Placebo|DRUG: Resveratrol 40 mg oral three times a day|DRUG: Resveratrol 500 mg oral once daily.
|
| Outcome Measures: |
Primary: NF-Kb, To investigate the effect of resveratrol on ROS generation and the pro-inflammatory transcription factor NF-kB, 12 weeks | Secondary: GLP-1, To see whether Resveratrol leads to a greater stimulation of the incretin system and secretion/release of GIP and GLP-1 when compared to that following placebo, 12 weeks
|
| Sponsor/Collaborators: |
Sponsor: University at Buffalo | Collaborators: Kaleida Health
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
|
| Enrollment: |
15
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: TREATMENT
|
| Start Date: |
2008-12
|
| Completion Date: |
2012-07-08
|
| Results First Posted: |
|
| Last Update Posted: |
2022-11-09
|
| Locations: |
Jeanne Hejna, Williamsville, New York, 14221, United States
|
| URL: |
https://clinicaltrials.gov/show/NCT01158417
|
